Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07247136Not ApplicableRecruiting

Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System

Role: lead

NCT07383688Not Yet Recruiting

FREEDOM Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics

Role: lead

NCT07144813Not ApplicableRecruiting

Post-Approval Study of the Neuspera Sacral Neuromodulation System

Role: lead

NCT04232696Not ApplicableActive Not Recruiting

Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Role: lead

NCT03643380Phase 1Completed

Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Role: lead

All 5 trials loaded